The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant

[1]  C. Towne.  The Rise and Fall of Prohibition: The Human Side of What the Eighteenth Amendment and the Volstead Act Have Done to the United States , 2017 .

[2]  B. Sessa.  MDMA and PTSD treatment “PTSD: From novel pathophysiology to innovative therapeutics” , 2017, Neuroscience Letters.

[3]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[4]  B. Schmidt,et al.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.

[5]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[6]  Kevin Murphy,et al.  Neural correlates of the LSD experience revealed by multimodal neuroimaging , 2016, Proceedings of the National Academy of Sciences.

[7]  C. Grob,et al.  MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  Kevin Murphy,et al.  The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity , 2015, Biological Psychiatry.

[9]  S. Seedat,et al.  Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. , 2015, The British journal of psychiatry : the journal of mental science.

[10]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[11]  Robert Patton,et al.  Alcohol related deaths in the UK , 2015 .

[12]  Felix Mario Schuldt.  MDMA-assisted psychotherapy for posttraumatic stress disorder , 2015 .

[13]  J. Corkery.  United Kingdom drug situation: annual report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2014 : Contributed to Chapter 6: Health correlates and consequences. , 2014 .

[14]  Christoph Eisenegger,et al.  MDMA enhances emotional empathy and prosocial behavior. , 2014, Social cognitive and affective neuroscience.

[15]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[16]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[17]  L. Jerome,et al.  A reconsideration and response to Parrott AC (2013) “Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research” , 2014, Human psychopharmacology.

[18]  H. Chabrol.  MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder , 2013, Journal of Psychopharmacology.

[19]  T. S. Krebs,et al.  Psychedelics and Mental Health: A Population Study , 2013, PloS one.

[20]  Tom Froese,et al.  Turing instabilities in biology, culture, and consciousness? On the enactive origins of symbolic material culture , 2013, Adapt. Behav..

[21]  U. Schnyder,et al.  A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD) , 2013, Journal of psychopharmacology.

[22]  L. Hides,et al.  Subacute effects of ecstasy on mood: an exploration of associated risk factors , 2013, Journal of psychopharmacology.

[23]  T. Brewerton,et al.  Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study , 2013, Journal of psychopharmacology.

[24]  G. Máté.  Addiction: Childhood Trauma, Stress and the Biology of Addiction , 2012 .

[25]  M. Mikulincer,et al.  An attachment perspective on psychopathology , 2012, World psychiatry : official journal of the World Psychiatric Association.

[26]  M. Liechti,et al.  MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions , 2012, Psychopharmacology.

[27]  Richard G. Wise,et al.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin , 2012, Proceedings of the National Academy of Sciences.

[28]  B. Sessa.  Could MDMA be useful in the treatment of post‐traumatic stress disorder? , 2011 .

[29]  L. Jerome,et al.  The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study , 2011, Journal of psychopharmacology.

[30]  Peter Hudson,et al.  Effective treatments for PTSD: practice guidelines from the International Society for Traumatic Stress Studies , 2011 .

[31]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[32]  B. Bradley,et al.  Substance use, childhood traumatic experience, and Posttraumatic Stress Disorder in an urban civilian population , 2010, Depression and anxiety.

[33]  L. Booth,et al.  Statistics on smoking , 2010 .

[34]  S. Rolles.  An alternative to the war on drugs , 2010, BMJ : British Medical Journal.

[35]  A. Pirona,et al.  An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users , 2010, Journal of psychopharmacology.

[36]  E. Croes,et al.  The Netherlands drug situation 2009 : report to the EMCDDA by the Reitox National Focal Point , 2010 .

[37]  B. Hankin,et al.  Insecure Attachment, Dysfunctional Attitudes, and Low Self-Esteem Predicting Prospective Symptoms of Depression and Anxiety During Adolescence , 2009, Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53.

[38]  E. Foa,et al.  Effective treatments for PTSD : practice guidelines from the International Society for Traumatic Stress Studies , 2009 .

[39]  D. Nutt,et al.  MDMA, politics and medical research: Have we thrown the baby out with the bathwater? , 2007, Journal of psychopharmacology.

[40]  I. McGregor,et al.  A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”) , 2007, Neuroscience.

[41]  C. Blakemore,et al.  Development of a rational scale to assess the harm of drugs of potential misuse , 2007, The Lancet.

[42]  P. Delgado,et al.  Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. , 2006, The Journal of clinical psychiatry.

[43]  Dan J Stein,et al.  Pharmacotherapy for post-traumatic stress disorder - a systematic review and meta-analysis. , 2006, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[44]  N. Gene-Cos.  Post-Traumatic Stress Disorder: The Management of PTSD in Adults and Children in Primary and Secondary Care , 2006 .

[45]  M. Morgan,et al.  The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans , 2006, Journal of psychopharmacology.

[46]  Wilson Compton,et al.  Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. , 2006, The Journal of clinical psychiatry.

[47]  Jonathan Burton,et al.  Estimating the size of the UK illicit drug market , 2006 .

[48]  Hscic.  Driving an Information Strategy for Health and Social Care in England 2006/2007 , 2006 .

[49]  S. Pilling,et al.  Post-traumatic stress disorder (PTSD): The management of PTSD in adults and children in primary and secondary care , 2005 .

[50]  K. Brady,et al.  Substance Abuse and Posttraumatic Stress Disorder , 2004 .

[51]  L. Webb,et al.  Review of deaths related to taking ecstasy, England and Wales, 1997-2000 , 2003, BMJ : British Medical Journal.

[52]  J. Mendelson,et al.  Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2002, Psychopharmacology.

[53]  J. Ours,et al.  Is Cannabis a Stepping-Stone for Cocaine? , 2001 .

[54]  T. B. Üstün,et al.  Cross-cultural views on stigma, valuation, parity, and societal values towards disability , 2001 .

[55]  B. A. van der Kolk,et al.  Down will Come Baby, Cradle and All: Diagnostic and Therapeutic Implications of Chronic Trauma on Child Development , 2000, The Australian and New Zealand journal of psychiatry.

[56]  F. Vollenweider,et al.  3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by (H 2 15 O)-PET in , 2000 .

[57]  J. Docherty,et al.  Investigation of the prejunctional α2‐adrenoceptor mediated actions of MDMA in rat atrium and vas deferens , 1999 .

[58]  A. Ruoho,et al.  Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines , 1999 .

[59]  J. Docherty,et al.  Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. , 1999, British Journal of Pharmacology.

[60]  A. Ruoho,et al.  Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. , 1999, European journal of pharmacology.

[61]  F. Vollenweider,et al.  Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers , 1998, Neuropsychopharmacology.

[62]  R. Hen,et al.  Insights into the Neurobiology of Impulsive Behavior from Serotonin Receptor Knockout Mice , 1997, Annals of the New York Academy of Sciences.

[63]  H. Curran,et al.  Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. , 1997, Addiction.

[64]  E. Krupitsky,et al.  Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. , 1997, Journal of psychoactive drugs.

[65]  R. Kessler,et al.  Posttraumatic stress disorder in the National Comorbidity Survey. , 1995, Archives of general psychiatry.

[66]  D. E. Nichols,et al.  Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors , 1994, Neuroscience Letters.

[67]  G. Greer,et al.  The Therapeutic Use of MDMA , 1990 .

[68]  J. A. Jahannes.  Substance abuse and the legacy of racism. , 1987, Journal of the National Medical Association.

[69]  G. Greer,et al.  Subjective reports of the effects of MDMA in a clinical setting. , 1986, Journal of psychoactive drugs.

[70]  D. Nichols,et al.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.